[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 29, 1974

Antenatal Diagnosis and Therapeutic Trends in Sphingolipidoses

Author Affiliations

From the Department of Neurology (Dr. Schneck), Kingsbrook Jewish Medical Center-Brooklyn Veterans Administration Hospital and the Birth Defects Center of the Isaac Albert Research Institute (Drs. Amsterdam and Volk), Brooklyn.

JAMA. 1974;228(5):615-618. doi:10.1001/jama.1974.03230300051034

OF the 1,500 distinguishable human diseases that are genetically determined, a recent review compiled more than 40 for which a prenatal diagnosis was potentially possible.1 This register includes diseases caused by chromosomal aberrations, sex-linked diseases, and metabolic disorders. In contrast to diseases that involve the interaction or blending of many different aberrant genes—polygenetic or multifactorial diseases—and usually appear somewhat later in life (eg, diabetes and atherosclerosis), metabolic diseases usually involve single gene mutations and adhere to the precepts of mendelian genetics. This means that armed with the appropriate information in regard to the dominant and recessive genetic traits, one can predict the statistical probability of the genetic nature of the offspring in regard to the disease entity.

In biochemical terms, the best understood group of genetic diseases are those in which a single gene mutation is involved, usually affecting the expression of an enzyme, hormone, or a particular protein.